Literature DB >> 6212171

Impaired primary in-vitro antibody response in progressive systemic sclerosis patients: rôle of suppressor monocytes.

P Segond, D Salliere, P Galanaud, R M Desmottes, P Massias, J N Fiessinger.   

Abstract

The primary in-vitro antibody response developed by peripheral blood mononuclear cells (PBM) towards trinitrophenyl coupled to polyacrylamide beads (TNP-PAA) was evaluated in 17 untreated patients with progressive systemic sclerosis (PSS). This response was markedly depressed as compared with that of 19 control patients and 28 normal subjects. In eight PSS patients and eight normal controls the anti-TNP response was measured before, and after, a PBM filtration on nylon wool columns. This procedure dramatically reduced the proportion of monocytes identified as mononuclear cells staining positively for peroxidases, and restored the response of PSS PBM to the level observed in normal PBM. In four experiments, plastic-adherent cells from either normal subjects of PSS patients were added to autologous nylon-passed PBM. This did not modify the response from normal PBM but inhibited the response of PSS PBM. The inhibitory effect of PSS plastic-adherent cells was insensitive to a 2,000 R X-ray irradiation. These results strongly suggest that the impaired in-vitro antibody response observed in PSS can be attributed to a suppressor monocyte. The concanavalin-A-induced suppressor cells of the antibody response were assayed in PSS. They exerted a suppressive effect to the same extent as in controls.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6212171      PMCID: PMC1536373     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Primary in vitro antibody response of human peripheral blood lymphocytes: role of phagocytic mononuclear cells.

Authors:  J F Delfraissy; P Galanaud; J Dormont; C Wallon
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

2.  Responses of fractionated cells from patients with systemic lupus erythematosus and normals to plant mitogen: evidence for a suppressor population of monocytes.

Authors:  J A Markenson; J W Morgan; M D Lockshin; C Joachim; J B Winfield
Journal:  Proc Soc Exp Biol Med       Date:  1978-05

3.  Identification by peroxidase staining of monocytes in surface immunofluorescence tests.

Authors:  J L Preud'homme; G Flandrin
Journal:  J Immunol       Date:  1974-11       Impact factor: 5.422

4.  The relationship of defective cell-mediated immunity to visceral disease in systemic sclerosis.

Authors:  P Hughes; S Holt; N R Rowell; I D Allonby; K Janis; J K Dodd
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

5.  Lymphocyte reactivity to mitogens in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma.

Authors:  D A Horwitz; M A Garrett
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

6.  Primary in vitro antibody response from human peripheral blood lymphocytes.

Authors:  J F Delfraissy; P Galanaud; J Dormont; C Wallon
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

7.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

8.  Induction of plaque-forming cells in human blood lymphocytes cultured in the presence of antigen and Epstein-Barr virus: a study with normal donors and infectious mononucleosis patients.

Authors:  A L Luzzati; I Heinzer; H Hengartner; M H Schreier
Journal:  Clin Exp Immunol       Date:  1979-03       Impact factor: 4.330

9.  Inhibition of polyclonal B-cell activation by suppressor monocytes in patients with sarcoidosis.

Authors:  P Katz; A S Fauci
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

10.  Selective decrease in antibody-dependent cell-mediated cytotoxicity in systemic lupus erythematosus and progressive systemic sclerosis.

Authors:  S M Cooper; B Harding; G R Mirick; J Schneider; F P Quismorio; G J Friou
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

View more
  2 in total

1.  Defective Epstein-Barr virus specific suppressor T cell function in progressive systemic sclerosis.

Authors:  A Kahan; A Kahan; C J Menkes; B Amor
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

2.  Increased production of an interleukin 1 (IL-1) inhibitor with fibroblast stimulating activity by mononuclear cells from patients with scleroderma.

Authors:  C I Sandborg; M A Berman; B S Andrews; G R Mirick; G J Friou
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.